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Alzheimer’s Research & Th erapy has published a series of 
articles written about the important new C9ORF72 muta-
tion associated with frontotemporal dementia (FTD) and 
amyotrophic lateral sclerosis (ALS). Th e clinical, neuro-
psychiatric and neuroimaging features of the patients 
who carry this mutation are discussed in this special 
series.
First reported in November 2011 [1,2], the C9ORF72 
mutation is the most common mutation associated with 
both FTD and ALS in the Western hemisphere and Europe 
(less is known about C9ORF72 in Asia and Africa). At the 
University of California, San Francisco (UCSF), the 
chromo some 9 (C9) expansion accounts for 53% of all 
familial ALS, FTD and ALS/FTD cases referred to the 
center, more common than all of the other FTD and AD 
mutations together. Th e Mayo Clinic found C9ORF72 
expansions accounted for 12% of familial FTD and 24% of 
familial ALS patients from a sequential series of their 
patients. Th ey also reported a 62% frequency in a 
University of British Columbia cohort of pathologically 
confi rmed frontotemporal lobar degeneration with 
TDP-43 pathology (FTLD-TDP) probands [1]. In Finland, 
the expansion accounts for 46% of familial ALS and 21% 
of sporadic ALS, while it accounts for 33% of familial ALS 
cases in people of European descent [2]. It is a gene with 
strong penetrance, and the vast majority of subjects with 
the C9 expansion die from a neurodegenerative 
condition. While some subjects with this mutation 
develop FTD-spectrum disorders, others exhibit ALS, 
while still others have a mixture of both FTD and ALS at 
the time of clinical presentation. Th e mutation brings up 
important questions regarding selec tive vulnerability and 
why one member of a family gets ALS while another dies 
from FTD that remain un answered.
Th e most common clinical manifestation of disease in 
gene carriers is behavioral variant frontotemporal 
dementia (bvFTD), and this mutation has its own unique 
anatomical features. Psychotic behaviors may suggest 
FTD due to C9ORF72 versus other types of bvFTD, but 
distinguishing clinical symptoms still need to be defi ned 
into a clear phenotype. While the frontal lobe 
degeneration in C9-related FTD may be less severe than 
that in patients with sporadic bvFTD, some of the 
patients with the C9ORF72 repeat appear to have more 
severe involvement of the thalamus [3,4] and cerebellum. 
How this degeneration intersects with the frontal 
involve ment and modifi es the clinical phenotype remains 
to be seen. Similarly, the neuropsychiatric prodrome of 
bvFTD and ALS in gene carriers needs to be better 
understood because early intervention will almost 
certainly be needed if eff ective therapies are going to be 
instituted.
C9 appears to mediate neurodegeneration via an RNA-
mediated mechanism. Th e repeat is located on a non-
coding region of C9ORF72, which encodes a protein with 
no known function that is expressed at high levels in the 
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An extremely long hexanucleotide repeat (usually 
greater than 400), appears to lead to ribonucleic acid 
aggregates within the nucleus and suppression of 
gene expression. Finding therapies for C9ORF72 will be 
diffi  cult and require novel therapeutic approaches that 
involve suppression of the expression of the C9ORF72 
repeat.
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brain. Th e extremely long hexanucleotide repeat (esti-
mated to be 700 to 1,600 units) appears to lead to RNA 
aggregates within the nucleus and suppression of gene 
expression through aberrant RNA splicing. Two other 
conditions, myotonic dystrophy and fragile-X-tremor-
ataxia, cause disease by a similar mechanism. A loss of 
C9ORF72 protein function is another possible mecha-
nism of disease. Finding therapies for C9ORF72 will be 
diffi  cult and require novel therapeutic approaches that 
involve suppression of the expression of the C9 repeat. 
Accurate animal models and well-characterized patient 
cohorts will be essential to understanding the underlying 
mechanisms of the disease pathway and the discovery of 
potential therapeutic targets. Such eff orts are underway 
in myotonic dystrophy and will soon be applied to the C9 
mutation.
Th is special series of Alzheimer’s Research & Th erapy 
expands our knowledge of C9ORF72 with articles on its 
clinical [5,6], imaging [7], genetic counseling [8] and 
treat ment aspects [9]. Clinical tests are available to 
screen for C9ORF72 expansions, but refi ning the clinical 
phenotype and imaging markers will help clarify when 
such testing is recommended. Genetic counseling is a 
critical service to help patients and families to decide 
when to test for the expansion, whether or not to learn 
the results and how to interpret the results. Both FTD 
and ALS [10] are described in this special series. Th e risk 
of C9ORF72 for FTD and ALS brings a new 
understanding to both disorders and brings us closer to 
the day when these diseases can be treated.
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